Catalyst Pharmaceuticals Stock Analysis

Catalyst Stock Analysis Notes

About 88.0% of the company shares are held by institutions such as insurance companies. The book value of Catalyst Pharmaceuticals was currently reported as 7.47. The company had not issued any dividends in recent years. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. For more info on Catalyst Pharmaceuticals please contact Richard MBA at 305 420 3200 or go to https://catalystpharma.com.

Catalyst Pharmaceuticals Investment Alerts

Catalyst Largest EPS Surprises

View All Earnings Estimates

Catalyst Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Catalyst Stock Institutional Investors

Note, although Catalyst Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Catalyst Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.99 B.

Catalyst Profitablity

The company has Profit Margin (PM) of 0.38 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.45 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.45.

Management Efficiency

Catalyst Pharmaceuticals has return on total asset (ROA) of 0.1774 % which means that it generated a profit of $0.1774 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2752 %, meaning that it created $0.2752 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.22 in 2026. Return On Capital Employed is likely to rise to 0.25 in 2026. At this time, Catalyst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 753 M in 2026, whereas Other Assets are likely to drop 1.09 in 2026.

Technical Drivers

As of the 16th of February 2026, Catalyst Pharmaceuticals shows the Mean Deviation of 1.52, downside deviation of 1.89, and Risk Adjusted Performance of 0.0876. Catalyst Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Catalyst Pharmaceuticals Price Movement Analysis

Catalyst Pharmaceuticals Insider Trading Activities

Catalyst Pharmaceuticals Outstanding Bonds

Catalyst Pharmaceuticals Predictive Daily Indicators

Catalyst Pharmaceuticals Corporate Filings

Catalyst Pharmaceuticals Forecast Models

Catalyst Pharmaceuticals' time-series forecasting models are one of many Catalyst Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Catalyst Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Catalyst Pharmaceuticals Bond Ratings

Catalyst Pharmaceuticals financial ratings play a critical role in determining how much Catalyst Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Catalyst Pharmaceuticals' borrowing costs.

Catalyst Pharmaceuticals Debt to Cash Allocation

Catalyst Pharmaceuticals currently holds 3.19 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Catalyst Pharmaceuticals has a current ratio of 10.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Catalyst Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Catalyst Pharmaceuticals Total Assets Over Time

Catalyst Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Catalyst Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Catalyst Pharmaceuticals Debt Ratio

0.41

It appears most of the Catalyst Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Catalyst Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Catalyst Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Catalyst Pharmaceuticals Corporate Bonds Issued

Catalyst Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Catalyst Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Catalyst shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Catalyst Pharmaceuticals. By using and applying Catalyst Stock analysis, traders can create a robust methodology for identifying Catalyst entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Catalyst analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Catalyst analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Catalyst Pharmaceuticals stock analysis indicators help investors evaluate how Catalyst Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Catalyst Pharmaceuticals shares will generate the highest return on investment. By understating and applying Catalyst Pharmaceuticals stock analysis, traders can identify Catalyst Pharmaceuticals position entry and exit signals to maximize returns.

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.